NCT00023309View on ClinicalTrials.gov

Lamivudine and Adefovir to Treat Chronic Hepatitis B

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

April 30, 2010

Study Completion Date

August 31, 2013

Conditions
HBV (Hepatitis B Virus)Hepatitis BHepatitis
Interventions
DRUG

Lamivudine and adefovir

Lamivudine (100 mg/day) and adefovir (10 mg/day)

DRUG

Adefovir alone

Adefovir (10 mg/day)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00023309 - Lamivudine and Adefovir to Treat Chronic Hepatitis B | Biotech Hunter | Biotech Hunter